SpringerProtocols: Abstract: Antisense Inhibition: Oligonucleotides, Ribozymes, and siRNAs

Antisense Inhibition: Oligonucleotides, Ribozymes, and siRNAs

By: Y. Clare Zhang², Meghan M. Taylor³, Willis K. Samson³, M. Ian Phillips⁴

Abstract

Full Text

Download PDF (175K)

Over a span of more than two decades, antisense strategies for gene therapy have expanded from antisense oligonucleotides (AS-ODNs) solely, to the addition of ribozymes and, more recently, to the inclusion of small interfering RNAs (siRNAs). Antisense therapeutics has also experienced its phases of high expectation, sudden disappointment, and meticulous rediscovery, while maintaining its status as a viable and effective gene therapy approach. With the discovery of RNA interference (RNAi) and development in delivery of these gene drugs, more preclinical and clinical investigations are anticipated to take place in the near future to finally fulfill the promise of antisense therapeutics in humans.

Affiliation(s): (2) Department of Pediatrics, University of South Florida, St. Petersburg, FL
(3) Department of Pharmacological and Physiological Science, St. Louis University, St. Louis, MO
(4) Vice President for Research, Office of Research, University of South Florida, Tampa, FL

Book Title: Antisense Therapeutics

Series: Methods in Molecular Medicine | Volume: 106 | Pub. Date: Sep-16-2004 | Page Range: 11-34 | DOI: 10.1385/1-59259-854-4:011

Subject: Cell Biology

References

Download References

1.	Zamecnik, P. C. and Stephenson, M. L. (1978) Inhibition of Pous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 75, 280–284.

2.	Schwartz, E. and Benz, E. (1995) Thalassemia Syndromes. Churchill Livingston, New York.

3.	Lacerra, G., Sierakowska, H., Carestia, C., et al. (2000) Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients. Proc. Natl. Acad. Sci. USA 97, 9591–9596.

4.	Mercatante, D. R., Bortner, C. D., Cidlowski, J. A., and Kole, R. (2001) Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. Analysis of apoptosis and cell death. J. Biol. Chem. 276, 16,411–16,417.

5.	Mathews, D. H., Sabina, J., Zuker, M., and Turner, D. H. (1999) Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J. Mol. Biol. 288, 911–940.

6.	Ho, S. P., Bao, Y., Lesher, T., et al. (1998) Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat. Biotechnol. 16, 59–63.

7.	Milner, N., Mir, K. U., and Southern, E. M. (1997) Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat. Biotechnol. 15, 537–541.

8.	Manoharan, M. (1999) 2′-carbohydrate modifications in antisense oligonucleotide therapy: importance of conformation, configuration and conjugation. Biochim. Biophys. Acta. 1489, 117–130.

9.	Morita, K, Takagi M, Hasegawa C, et al. (2002) 2′-O,4′-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. Bioorg. Med. Chem. Lett. 12, 73–76.

10.	Summerton, J. (1999) Morpholino antisense oligomers: the case for an RNase—independent structure type. Biochim. Biophys. Acta 1489, 141–158.

11.	Elayadi, A. N. and Corey, D. R. (2001) Application of PNA and LNA oligomers to chemotherapy. Curr. Opin. Investig. Drugs 2, 558–561.

12.	Declercq, R., Van Aerschot, A., Read, R. J., Herdewijn, P., and Van Meervelt, L. (2002) Crystal structure of double helical hexitol nucleic acids. J. Am. Chem. Soc. 124, 928–933.

13.	Wang, H., Wang, S., Nan, L., Yu, D., Agrawal, S., and Zhang, R. (2002) Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: in vivo activity and mechanisms. Int. J. Oncol. 20, 745–752.

14.	Maurer, N., Fenske, D. B., and Cullis, P. R. (2001) Developments in liposomal drug delivery systems. Expert Opin. Biol. Ther. 1, 923–947.

15.	Brigger, I., Dubernet, C., and Couvreur, P. (2002) Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 54, 631–651.

16.	Manoharan, M. (2002) Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action. Antisense Nucleic Acid Drug Dev. 2, 103–128.

17.	Lecocq, M., Andrianaivo, F., Warnier, M. T., Wattiaux-De Coninck, S., Wattiaux, R., and Jadot, M. (2003) Uptake by mouse liver and intracellular fate of plasmid DNA after a rapid tail vein injection of a small or a large volume. J. Gene Med. 5, 142–156.

18.	Sandrasagra, A., Leonard, S. A., et al. (2002) Discovery and development of respirable antisense therapeutics for asthma. Antisense Nucleic Acid Drug Dev. 12, 177–181.

19.	Brand, R. M. (2001) Topical and transdermal delivery of antisense oligonucleotides. Curr. Opin. Mol. Ther. 3, 244–248.

20.	Reynolds, T. (1992) First antisense drug trials planned in leukemia. J. Natl. Cancer Inst. 84, 288–290.

21.	Roehr, B. (1998) Fomivirsen approved for CMV retinitis. J. Int. Assoc. Physicians AIDS Care 4, 14–16.

22.	Altman, S. (1990) Ribonuclease P. Postscript. J. Biol. Chem. 265, 20,053–20,056.

23.	Cech, T. R. (1987) The chemistry of self-splicing RNA and RNA enzymes. Science 236, 1532–1539.

24.	Esteban, J. A., Banerjee, A. R., and Burke, J. M. (1997) Kinetic mechanism of the hairpin ribozyme. J. Biol. Chem. 272, 13,629–13,639.

25.	Fedor, M. J. and Uhlenbeck, O. C. (1992) Kinetics of intermolecular cleavage by hammerhead ribozymes. Biochemistry 31, 1242–1254.

26.	Symons, R. H. (1992) Small catalytic RNAs. Annu. Rev. Biochem. 61, 641–671.

27.	Birikh, K. E., Heaton, P. A., and Eckstein, F. (1997) The structure, function and application of the hammerhead ribozyme. Eur. J. Biochem. 245, 1–16.

28.	Dahm, S. C. and Uhlenbeck, O. C. (1991) Role of divalent metal ions in the hammerhead RNA cleavage reaction. Biochemistry 30, 9464–9469.

29.	Lieber, A. and Strauss, M. (1995) Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Mol. Cell. Biol. 15, 540–551.

30.	Hendry, P. and McCall, M. (1996) Unexpected anisotropy in substrate cleavage rates by asymmetric hammerhead ribozymes. Nucleic Acids Res. 24, 2679–2684.

31.	Fedor, M. J. (2000) Structure and function of the hairpin ribozyme. J. Mol. Biol. 297, 269–291.

32.	Young, K. J., Gill, F., and Grasby, J. A. (1997) Metal ions play a passive role in the hairpin ribozyme catalyzed reaction. Nucleic Acids Res. 25, 3760–3766.

33.	Li, Y. and Breaker, R. R. (1999) Deoxyribozymes: new players in the ancient game of biocatalysis. Curr. Opin. Struct. Biol. 9, 315–323.

34.	Riddell, S. R., Elliott, M., Lewinsohn, D. A., et al. (1996) T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV infected patients. Nat. Med. 2, 216–223.

35.	Taylor, M. M. and Samson, W. K. (2002) Ribozyme compromise of adrenomedullin mRNA reveals a physiological role in the regulation of water intake. Am. J. Physiol. 282, R1739–R1745.

36.	Koizumi, M., Hayase, Y., Iwai, S., et al. (1989) Design of a RNA enzyme distinguishing a single base mutation in RNA. Nucleic Acids Res. 17, 7059–7071.

37.	Koizumi, M., Kmiya, H., and Ohtsuka, D. (1992) Ribozymes designed to inhibit transformation of NIH/3T3 cells by the activated c-Ha-ras gene. Gene 117, 179–184.

38.	Usman, N. and Blatt, L. M. (2000) Nuclease-resistant synthetic ribozymes: developing a new class of therapeutics. J. Clin. Invest. 106, 1197–1202.

39.	Lewin, A. S., Drenser, K. A., Hauswirth, W. W., et al. (1998) Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nat. Med. 4, 967–971.

40.	Lavail, M. M., Yasumura, D., Matthes, M. T., et al. (2000) Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy. Proc. Nat. Acad. Sci. USA 97, 11,488–11,493.

41.	Muotri, A. R., Pereira, L. V., Vasques, L. R., et al. (1999) Ribozymes and the antigene therapy: how a catalytic RNA can be used to inhibit gene function. Gene 237, 303–310.

42.	Guo, S. and Kemphues, K. J. (1995) Par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell 81, 611–620.

43.	Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., and Mello, C. C. (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806–811.

44.	Zamore, P. D., Tuschl, T., Sharp, P. A., and Bartel, D. P. (2000) RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 101, 25–33.

45.	Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001) RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev. 15, 188–200.

46.	Bernstein, D., Caudy, A. A., Hammond, S. M., and Hannon, G. J. (2001) Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409, 363–366.

47.	Hammond, S. M., Bernstein, F., Beach, D., and Hannon, G. J. (2000) An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404, 293–296.

48.	Stark, G. R., Kerr, I. M., Williams, B. R., et al. (1998) How cells respond to interferons. Annu. Rev. Biochem. 67, 227–264.

49.	Minks, M. A., West, D. K., Benvin, S., and Baglioni, C. (1979) Structural requirements of double-stranded RNA for the activation of 2′,5′-oligo(A) polymerase and protein kinase of interferon-treated Hela cells. J. Biol. Chem. 254, 10,180–10,183.

50.	Elbashir, S. M., Harborth, J., Lendeckel, W., et al. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494–498.

51.	McManus, M. T. and Sharp, P. A. (2002) Gene silencing in mammals by small interfering RNAs. Nat. Rev. 3, 737–747.

52.	Shi, Y. (2003) Mammalian RNAi for the masses. Trends Genet. 19, 9–12.

53.	Song, E., Lee, S. K., Wang, J., et al. (2003) RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9, 347–351.

54.	Sorensen, D. R., Leirdal, M., and Sioud, M. (2003) Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J. Mol. Biol. 327, 761–766.

55.	Herweijer, H. and Wolff, J. A. (2003) Progress and prospects: naked DNA gene transfer and therapy. Gene Ther. 10, 453–458.

56.	Czauderna, F., Fechtner, M., Dames, S., et al. (2003) Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells. Nucleic Acid Res. 31, 2705–2716.

57.	Chiu, Y. L. and Rana, T. M. (2002) RNAi in human cells: basic structural and functional features of small interfering RNA. Mol. Cell 10, 549–561.

58.	Holen, T., Amarzguioui, M., Wiiger, M. T., Babaie, E., and Prydz, H. (2002) Positional effects of short interfering RNAs targeting the human coagulation trigger tissue factor. Nucleic Acids Res. 30, 1757–1766.

59.	Amarzguioui, M., Holen, T., Babaie, E., and Prydz, H. (2003) Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 31, 589–595.

60.	Harborth, J., Elbashir, S. M., Vandenburgh, K., et al. (2003) Sequence, chemical, and structural variation of small interfering rnas and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. 13, 83–105.

61.	Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002; 26: 199–213.

62.	MaManus, M. T., Haines, B. B., Chen, J,. and Sharp, P. A. (2002) SiRNA-mediated gene silencing in T-lymphocytes. J. Immunol. 169, 5754–5760.

63.	Jacque, J. M., Triques, K., and Stevenson, M. (2002) Modulation of HIV-1 replication by RNA interference. Nature 418, 435–438.

64.	Novina, C. D., Murray, M. F., Dykxhoorn, D. M., et al. (2002) siRNA-directed inhibition of HIV-1 infection. Nat. Med. 8, 681–686.

65.	Surabhi, R. M. and Gaynor, R. B. (2002) RNA interference directed against viral and cellular targets inhibits human immunodeficiency virus type 1 replication. J. Virol. 76, 12,963–12,973.

66.	Capodici, J., Kariko, K., and Weissman, D. (2002) Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference. J. Immunol. 169, 5196–5201.

67.	Coburn, G. A. and Cullen, B. R. (2002) Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. J. Virol. 76, 9225–9231.

68.	Lee, N. S., Dohjima, T., Bauer, G., Li, H., et al. (2002) Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol. 20, 500–505.

69.	Yokota, T., Sakamoto, N., Enomoto, N., et al. (2003) Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO Rep. 4, 602–608.

70.	Wilson, J. A., Jayasena, S., Khvorova, A., et al. (2003) RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc. Natl. Acad. Sci. USA 100, 2783–2788.

71.	Kapadia, S. B., Brideau-Andersen, A., and Chisari, F. V. (2003) Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc. Natl. Acad. Sci. USA 100, 2014–2018.

72.	Randall, G., Grakoui, A., and Rice, C. M. (2003) Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc. Natl. Acad. Sci. USA 100, 235–240.

73.	Seo, M. Y., Abrignani, S., Houghton, M., and Han, J. H. (2003) Small interfering RNA-mediated inhibition of hepatitis C virus replication in the human hepatoma cell line Huh-7. J. Virol. 77, 810–812.

74.	McCaffrey, A. P., Meuse, L., Pham, T. T., Conklin, D. S., Hannon, G J., and Kay, M. A. (2002) RNA interference in adult mice. Nature 418, 38–39.

75.	Hamasaki, K., Nakao, K., Matsumoto, K., Ichikawa, T., Ishikawa, H., and Eguchi, K. (2003) Short interfering RNA-directed inhibition of hepatitis B virus replication. FEBS Lett. 543, 51–54.

76.	McCaffery, A. P., Nakai, H., Pandey, K., et al. (2003) Inhibition of hepatitis B virus in mice by RNA interference. Nat. Biotechnol. 21, 639–644.

77.	Shlomai, A. and Shaul, Y. (2003) Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology 37, 764–770.

78.	Hall, A. H. and Alexander, K. A. (2003) RNA interference of human papillomavirus type 18 E6 and E7 induces senescence in Hela cells. J. Virol. 77, 6066–6069.

79.	Jia, Q. and Sun, R. (2003) Inhibition of gammaherpesvirus replication by RNA interference. J. Virol. 77, 3301–3306.

80.	Dector, M. A., Romero, P., Lopez, S., and Arias, F. (2002) Rotavirus gene silencing by small interfering RNAs. EMBO Rep. 3, 1175–1180.

81.	Ge, Q., McManus, M. T., Nguyen, T., et al. (2003) RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc. Natl. Acad. Sci. USA 100, 2718–2723.

82.	Gitlin, L., Karelsky, S., and Andino, R. (2002) Short interfering RNA confers intracellular antiviral immunity in human cells. Nature 418, 430–434.

83.	Miyagishi, M., Hayashi, T., and Taira, K. (2003) Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev. 13, 1–7.

84.	Bertrand, J. R., Pottier, M., Vekris, A., et al. (2002) Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun. 29, 1000–1004.

85.	Aoki, Y., Cioca, D. P., Oidaira, H., Kamiya, J., and Kiyosawa, K. (2003) RNA interference may be more potent than antisense RNA in human cancer cell lines. Clin. Exp. Pharmacol. Physiol. 30, 96–102.

86.	Garber, K. (2003) Better blocker: RNA interference dazzles research community. J. Natl. Cancer Inst. 95, 500–502.

87.	Vickers, T. A., Koo, S., Bennett, C. F., Crooke, S. T., Dean, N. M., and Baker, B. F. (2003) Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. J. Biol. Chem. 278, 7108–7118.

88.	Hemmings-Mieszczak, M., Dorn, G., Natt, F. J., et al. (2003) Independent combinatorial effect of antisense oligonucleotides and RNAi-mediated specific inhibition of the recombinant rat P2X3 receptor. Nucleic Acids Res. 31, 2117–2126.

89.	Yu, J. Y., DeRuiter, S. L., and Turner, D. L. (2002) RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc. Natl. Acad. Sci. USA 99, 6047–6052.

90.	Paddison, P. J., Caudy, A. A., Bernstein, E., et al. (2002) Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 16, 948–958.

91.	Brummelkamp, T. R., Bernards, R., and Agami, R. (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550–553.

92.	Paul, C. P., Good, P. D., Winer, I., and Engelke, D. R. (2002) Effective expression of small interfering RNA in human cells. Nat. Biotechnol. 20, 505–508.

93.	Miyagishi, M. and Taira, K. (2002) U6 promoter driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat. Biotechnol. 20, 497–500.

94.	Sui, G., Soohoo, C., Affar, B., et al. (2002) A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA 99, 5515–5520.

95.	Kawasaki, H. and Taira, K. (2003) Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res. 31, 700–707.

96.	Zeng, Y., Wagner, E. J., and Cullen, B. R. (2002) Both natural and designed microRNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol. Cell. 9, 1–20.

97.	Xia, H., Mao, Q., Paulson, H. L., and Davidson, B. (2002) siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol. 20, 1006–1010.

98.	Barton, G. M. and Medzhitov, R. (2002) Retroviral delivery of small interfering RNA into primary cells. Proc. Natl. Acad. Sci. USA 99, 14,943–14,945.

99.	Rubinson, D. A., Dillon, C. P., Dwiatkowski, A. U., et al. (2003) A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference. Nat. Genet. 33, 401–406.

100.	Tiscornia, G., Singer, O., Ikawa, M., and Verma, I. M. (2003) A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc. Natl. Acad. Sci. USA 100, 1844–1848.

101.	Shen, C., Buck, A. K., Liu, X., Winkler, M., and Reske, S. W. (2003) Gene silencing by adenovirus-delivered siRNA. FEBS Lett. 539, 111–114.

102.	Stewart, S. A., Dykxhoorn, D, M., Palliser, D., et al. (2003) Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 9, 493–501.

103.	Dirac, A. M. and Bernards, R. (2003) Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J. Biol. Chem. 278, 11,731–11,734.

104.	Brummelkamp, T. R., Bernards, R., and Agami, R. (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243–247.

105.	Hasuwa, H., Kaseda, K., Einarsdottir, T., and Okabe, M. (2002) Small interfering RNA and gene silencing in transgenic mice and rats. FEBS Lett. 532, 227–230.

106.	Kunath, T., Gish, G., Lickert, H., Jones, N., Pawson, T., and Rossant, J. (2003) Transgenic RNA interference in ES cell-derived embryos recapitulates a genetic null phenotype. Nat. Biotechnol. 21, 559–561.

107.	Reich, S. J., Fosnot, J., Kuroki, A., et al. (2003) Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model. Mol. Vis. 9, 210–216.

108.	Verma UN, Surabhi, R. M., Schmalties, A., Becerra, C., and Gaynor, R. B. (2003) Small interfering RNAs directed against beta-catenin inhibits the in vitro and in vivo growth of colon cancer cells. Clin. Cancer Res. 9, 1291–300.

109.	Makimura, H., Mizunno, T. M., Mastaitis, J. W., Agami, R., and Mobbs, C. V. (2002) Reducing hypothalamic AGRP by RNA interference increases metabolic rate and decreases body weight without influencing food intake. BMC Neurosci. 3, 18.

110.	Lewis, D. L., Hagstrom, J. E., Loomis, A. G., Wolff, J. A., and Herweijer, H. (2002) Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat. Genet. 32, 107–108.

Comments (Loading...)

Post comment/View all comments